PCSK9在心血管疾病中的研究进展
Research progress on role of PCSK9 in cardiovascular disease
杜林芳 1练静 1李阳 2魏晓丽 1马恒3
作者信息
- 1. 延安大学基础医学院,陕西延安 710600
- 2. 陕西中医药大学基础医学院,陕西咸阳 712046
- 3. 空军军医大学基础医学院生理与病理生理学教研室;陕西西安 710032
- 折叠
摘要
前蛋白转化酶枯草溶菌素 9(protein convertase subtilisin/kexin type 9,PCSK9)是一种丝氨酸蛋白酶,主要产生于肝脏.作为前蛋白转化酶家族中的一员,PCSK9可以与低密度脂蛋白受体(low-density lipoprotein receptor,LDLR)结合使其进入溶酶体进行降解,从而抑制LDLR再循环到细胞表面发挥清除血浆中的低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)的功能,进而导致高胆固醇血症.近年的研究显示PCSK9与心血管疾病的发生发展有着紧密的联系,所以PCSK9在心血管疾病研究中显示出作为新治疗靶点的可能性.本文以PCSK9为切入点,总结论述其结构、功能并概述了PCSK9在多种心血管疾病中的研究进展.
Abstract
Proprotein convertase subtilisin/kexin type 9(PCSK9)is a serine protease that is produced mainly in the liver.As a member of the proprotein convertase family,PCSK9 binds to the LDL receptor(low-density lipoprotein receptor(LDLR)to allow it to enter the lysosome for degradation,thereby inhibiting the recirculation of LDLR to the cell surface for removal of plasma LDL cholesterol(low-density lipoprotein cholesterol,LDL-C).This inhibits the recirculation of LDLR to the cell surface to perform the function of removing low-density lipoprotein cholesterol(LDL-C)from plasma,which leads to hypercholesterolemia.Existing studies have shown that PCSK9 is closely associated with the development of various cardiovascular diseases and has shown the potential as a new therapeutic target in cardiovascular disease research.Here,we summarize the structure and function of PCSK9 as an entry point and review the progress of PCSK9 research in various cardiovascular diseases.
关键词
前蛋白转化酶枯草溶菌素9/LDL受体/心血管疾病Key words
PCSK9/LDLR/cardiovascular disease引用本文复制引用
基金项目
国家自然科学基金(82070261)
国家自然科学基金(82170251)
国家自然科学基金(82100312)
出版年
2024
NETL
NSTL
万方数据